Trans fat labeling study
This article was originally published in The Tan Sheet
Executive Summary
FDA is seeking comment on a proposed experimental study of trans fat claims on foods, according to a Federal Register notice slated for publication Feb. 6. The study would "evaluate the effect of various possible disclosure requirements intended to help consumers understand and apply trans fat claims they might see on food products," the agency explains. The proposed study would be conducted online among roughly 2,880 adult respondents, FDA states. Data gathered from the study would be used to "assess likely consumer responses to various disclosure requirements for nutrient content claims." The compliance date for FDA's requirement that products containing trans fat be appropriately labeled was Jan. 1 (1"The Tan Sheet" July 14, 2003, p. 7). Comments on the proposal are due by April 7...
You may also be interested in...
Supplement Trans Fat Label Additions Stipulated Under FDA Final Rule
Manufacturers of dietary supplements that contain more than .5 g of trans fat will be required to list the amount of the ingredient, as well as the amounts of saturated fat and cholesterol, on the Supplement Facts panel by Jan. 1, 2006
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.